share_log

Press Release: Integra LifeSciences Reports Third -4-

Press Release: Integra LifeSciences Reports Third -4-

新聞稿：Integra LifeSciences報告第三季度第四季度
Dow Jones Newswires ·  2021/11/02 18:00

(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.

(1)收購、剝離和整合相關費用與Codman神經外科、Arkis生物科學、反彈治療和ACell收購以及剝離Extremity Orthopedics有關，包括銀行、法律、諮詢、系統和其他收入和支出。

(2) Upon adoption of ASU No. 2020-06, the Company will no longer incur non-cash interest expense for the amortization of debt discount.

(2)採用ASU第2020-06號文件後，本公司將不再發生債務折價攤銷的非現金利息支出。

RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE

非GAAP調整-GAAP淨收入與調整後淨收入和調整後每股收益的衡量標準

(UNAUDITED)

(未經審計)

(In thousands, except per share amounts)

(單位為千，每股除外)

                                       Three Months Ended September 30, 
                                  ------------------------------------------ 
                                          2021                  2020 
                                  --------------------  -------------------- 
GAAP net income                             43,229                32,337 
Non-GAAP adjustments: 
Structural optimization charges              6,696                 4,543 
Acquisition, divestiture and 
 integration-related charges(1)              2,637                 7,148 
COVID-19 related charges                        --                  (193) 
EU Medical Device Regulation 
 charges                                     7,077                 2,399 
Discontinued product lines 
 charges                                        23                   999 
Intangible asset amortization 
 expense                                    20,248                20,180 
Expenses related to debt 
 refinancing                                    --                 3,428 
Convertible debt non-cash 
 interest (2)                                   --                 4,295 
Estimated income tax impact from 
 adjustments and other items                (6,853)               (7,433) 
                                  ----------------      ---------------- 
      Total of non-GAAP 
       adjustments                          29,828                35,366 
                                  ----------------      ---------------- 
Adjusted net income                $        73,058       $        67,703 
                                      ------------          ------------ 
Adjusted diluted net income per 
 share                             $          0.86       $          0.80 
Weighted average common shares 
 outstanding for diluted net 
 income per share                           85,447                84,752 
截至9月30日的三個月，                                  ------------------------------------------                                           2021                  2020                                   --------------------  -------------------- 公認會計準則淨收益43,229 32,337非GAAP調整：結構優化費用6696 4543收購、剝離和與融合有關的收費(1)2637 7148新冠肺炎相關收費--(193)歐盟醫療器械法規收費7,077,399停產產品線收費23999無形資產攤銷費用20,248 20,180與債務有關的費用再融資--3,428可轉換債務非現金利息(2)--4,295估計所得税的影響來自調整和其他項目(6853)(7433)                                  ----------------      ---------------- 非GAAP合計調整29,828 35,366                                  ----------------      ---------------- 調整後淨收入73,058美元67,703美元                                      ------------          ------------ 調整後稀釋淨收入每股0.86美元0.80美元加權平均普通股未清償稀釋淨額每股收益85,447 84,752

(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.

(1)收購、剝離和整合相關費用與Codman神經外科、Arkis生物科學、反彈治療和ACell收購以及剝離Extremity Orthopedics有關，包括銀行、法律、諮詢、系統和其他收入和支出。

(2) Upon adoption of ASU No. 2020-06, the Company will no longer incur non-cash interest expense for the amortization of debt discount.

(2)採用ASU第2020-06號文件後，本公司將不再發生債務折價攤銷的非現金利息支出。

CONDENSED BALANCE SHEET DATA

濃縮資產負債表數據

(UNAUDITED)

(未經審計)

(In thousands)

(單位：千)

                                          September 30,     December 31, 
                                               2021             2020 
                                         ---------------  ---------------- 
Cash and cash equivalents                 $      470,231   $     470,166 
Trade accounts receivable, net                   222,232         225,532 
Inventories, net                                 327,167         310,117 
Current and long-term borrowing under 
 senior credit facility                          868,736         967,137 
Borrowings under securitization 
 facility                                        111,700         112,500 
Long-term convertible securities                 563,697         474,834 
Stockholders' equity                      $    1,631,687   $   1,514,867 
                                             -----------      ---------- 
九月三十日，十二月三十一日，                                               2021             2020                                          ---------------  ---------------- 現金及現金等價物$470,231$470,166應收貿易賬款，淨額222,232 225,532庫存，淨額327,167 310,117項下的經常和長期借款高級信貸安排868,736 967,137證券化下的借款設施111,700 112,500長期可轉換證券563,697,474,834股東權益$1,631,687$1,514,867                                             -----------      ----------

CONDENSED STATEMENT OF CASH FLOWS

簡明現金流量表

(UNAUDITED)

(未經審計)

(In thousands)

(單位：千)

                                       Nine Months Ended September 30, 
                                           2021                 2020 
                                   ---------------------  ---------------- 
Net cash provided by operating 
 activities                         $        243,150      $     123,570 
Net cash used in investing 
 activities                                 (133,958)           (32,152) 
Net cash (used) provided by 
 financing activities                        (98,747)           100,403 
Effect of exchange rate changes 
 on cash and cash equivalents                (10,380)             5,547 
                                   -----------------      ------------- 
Net increase (decrease) in cash 
 and cash equivalents               $             65      $     197,368 
                                       -------------       ------------ 
截至9月30日的9個月，                                           2021                 2020                                    ---------------------  ---------------- 運營提供的淨現金活動$243,150$123,570用於投資的淨現金活動(133,958)(32,152)提供的淨現金(已用)融資活動(98,747)100,403匯率變動的影響關於現金和現金等價物(10,380)5,547                                   -----------------      ------------- 現金淨增(減)和現金等價物$65$197,368                                       -------------       ------------

RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO

非GAAP調整的對賬-GAAP營業現金流

MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION

自由現金流量和調整後自由現金流量換算的計量

(UNAUDITED)

(未經審計)

(In thousands)

(單位：千)

                                     Three Months Ended September 30, 
                                          2021                 2020 
                                 ----------------------  ----------------- 
Net cash provided by operating 
 activities                       $        82,778        $     69,643 
                                     ------------  ----   -----------  --- 
Purchases of property and 
 equipment                                 (7,286)             (6,727) 
                                 ----------------   ---  ------------ 
Free cash flow                             75,492              62,916 
Adjusted net income(1)            $        73,058        $     67,703 
                                     ------------  ----   -----------  --- 
Adjusted free cash flow 
 conversion                                 103.3%               92.9% 
                                     Twelve Months Ended September 30, 
                                          2021                 2020 
                                 ----------------------  ----------------- 
Net cash provided by operating 
 activities                       $       323,414        $    212,757 
Purchases of property and 
 equipment                                (29,023)            (52,656) 
Adjusted free cash flow                   294,391             160,101 
Adjusted net income(1)            $       270,780        $    196,266 
                                     ------------  ----   -----------  --- 
Adjusted free cash flow 
 conversion                                 108.7%               81.6% 
截至9月30日的三個月，                                          2021                 2020                                  ----------------------  ----------------- 運營提供的淨現金活動$82,778$69,643                                     ------------  ----   -----------  --- 購買物業及設備(7286)(6727)                                 ----------------   ---  ------------ 自由現金流75,492 62,916調整後淨收入(1)$73,058$67,703                                     ------------  ----   -----------  --- 調整後的自由現金流轉換率103.3%92.9%截至9月30日的12個月，                                          2021                 2020                                  ----------------------  ----------------- 運營提供的淨現金活動$323,414$212,757購買物業及設備(29,023)(52,656)調整後自由現金流294,391 160,101調整後淨收入(1)270,780美元196,266美元                                     ------------  ----   -----------  --- 調整後的自由現金流轉換率108.7%81.6%

(1) Adjusted net income for quarters ended September 30, 2020 and 2021 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations.

(1)截至2020年9月30日和2021年9月30日的季度調整後淨收入如上所示。在過去12個月的計算中，其餘季度的調整後淨收入以前已經過調整，並在我們的網站Investor.Integralife.com上的活動和演示下的季度收益電話會議上公開提供。

The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.

該公司通過將其自由現金流除以調整後的淨收入來計算調整後的自由現金流轉換。該公司相信，這一衡量標準有助於評估現金特別費用在其調整後收益衡量標準中的重要性。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論